聚和聚纳米和微载体用于药物输送
Stanislaw Slomkowski1, Teresa Basinska1, Mariusz Gadzinowski1
1Division of Functional Polymers and Polymer Materials, Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, H. Sienkiewicza 112, 90-363 Lodz, Poland.
Polymers
|September 14, 2024
概括
阿里法性聚合物为向药物输送提供了多功能聚合物纳米载体,最大限度地减少了免疫反应. 本综述涵盖了它们的合成,药物负载和各种癌症的临床应用.
科学领域:
- 聚合物化学 聚合物化学
- 纳米技术纳米技术
- 材料科学 材料科学 材料科学
背景情况:
- 治疗性输送通常需要携带者来保护药物免受免疫系统和健康组织的影响.
- 存在各种纳米载体,包括无机纳米粒子,脂质体和基于聚合物的系统.
- 亚利法性聚合物是开发定制纳米载体的关键聚合物类别.
研究的目的:
- 审查用于纳米载体制备的阿里法性聚合物的受控合成.
- 讨论将药物装入这些纳米载体的方法.
- 介绍聚纳米载体的研究成果,用于向药物输送和临床应用.
主要方法:
- 控制合成的阿里法性聚合物,如聚-β-烯酸,聚酸,聚糖化物,和聚-ε-烯酸).
- 使用双键共聚合物制备功能化纳米粒子.
- 应用各种药物加载技术,包括纳米沉和直接合成方法.
- 针对大脑向药物输送的体外和体内研究.
主要成果:
- 合成具有可控摩尔质量和微观结构的异质聚合物.
- 使用多种制备方法开发载有药物的纳米载体.
- 证明脑向治疗的体外和体内疗效.
- 临床研究和批准的聚纳米载体配方的最新情况.
结论:
- 阿里法性聚合物为先进的药物输送系统提供了一个可调节的平台.
- 控制的合成和配方方法可以创建有效的纳米载体.
- 聚纳米载体在癌症治疗的临床环境中表现有前途.
相关概念视频
Modified-Release Drug Delivery Systems: Rate-Programmed II
91
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
91
Modified-Release Drug Delivery Systems: Classification
264
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
264
Modified-Release Drug Delivery Systems: Stimuli-Activated
124
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
124
Modified-Release Drug Delivery Systems: Site-Targeted
113
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
113
Site-Targeted Drug Delivery Systems: Polymeric Carriers
115
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
115
Oral Drug Delivery Systems: Delayed-Release Systems
153
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
153


